MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

SpringWorks Therapeutics Inc

Cerrado

SectorSalud

46.51 11.53

Resumen

Variación precio

24h

Actual

Mínimo

41.08

Máximo

46.89

Métricas clave

By Trading Economics

Ingresos

-24M

-77M

Ventas

12M

62M

BPA

-1.04

Margen de beneficio

-125.586

Empleados

368

EBITDA

-23M

-80M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+71.23% upside

Dividendos

By Dow Jones

Próximas Ganancias

1 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-839M

3.3B

Apertura anterior

34.98

Cierre anterior

46.51

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

180 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

SpringWorks Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 feb 2025, 07:03 UTC

Adquisiciones, fusiones, absorciones

Germany's Merck in Talks to Buy SpringWorks Therapeutics

10 feb 2025, 16:38 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

11 feb 2025, 10:54 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

11 feb 2025, 10:52 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Comparación entre iguales

Cambio de precio

SpringWorks Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

71.23% repunte

Estimación a 12 meses

Media 71.71 USD  71.23%

Máximo 87 USD

Mínimo 63 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para SpringWorks Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

44.13 / 47.505Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

180 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.